Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05007470 · ClinicalTrials.gov registry record · NA
Alcoholic Liver Disease and the Gut Microbiome
A NA study of Alcohol Use Disorder and Microbiome, sponsored by University of California, Los Angeles.
- Active
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05007470 is a NA study of Alcohol Use Disorder and Microbiome that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 80 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05007470, a NA study of Alcohol Use Disorder and Microbiome, is active but no longer recruiting, sponsored by University of California, Los Angeles.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Significant sex differences exist in regard to alcohol use disorder (AUD) and alcoholic liver disease (ALD). To date, no studies have examined the brain-gut-microbiome (BGM) axis (which is the relationship between the gut, brain, and the bacteria within the gut) and sex-differences in AUD and ALD. Aims: 1) Demonstrate baseline sex differences in the microbiome and metatranscriptome of AUD and ALD and correlate those differences to severity, 2) determine if these baseline sex differences predicts abstinence or ALD related outcomes, and 3) show how altering the microbiome can decrease the severity of AUD and ALD in a sexdependent manner. Hypothesis: Our project is aimed to explore the hypothesis that sex-related differences of the BGM axis in AUD and ALD explains the variation in patient severity and outcome by sex, and that alterations of the BGM axis can decrease the severity of AUD and ALD in a sex-dependent manner. Methods: A pilot randomized placebo (VSL#3 vs placebo) control trial will be performed in patients with AUD and ALD for 6 months. Questionnaire data, clinical labs, serum, and feces for shotgun metagenomics will be collected at baseline, 3-months, and 6-months. Anticipated Results: Patients with severe AUD/ALD will have more microbes and microbial genes associated with inflammation. These differences will predict outcomes at 6-months and that changes of this baseline microbiome with VSL#3 will lead to more positive outcomes than placebo, with men having greater benefit from VSL#3 than women. Implications and Future Studies: The discovery of the mechanisms underlying sex-related differences in AUD/ALD is needed for the development of personalized recommendations for prevention and treatment in men and women
Conditions Studied
Interventions
- OTHER Placebo
- DRUG VSL #3 112.5 Capsule
Study Locations (1)
California
- University of California, Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-01-31 |
| Est. Completion | 2025-09-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05007470
The ClinicalTrials.gov registry entry for NCT05007470 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (76% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05007470 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05007470 about?
NCT05007470 is a clinical study titled "Alcoholic Liver Disease and the Gut Microbiome". Background: Significant sex differences exist in regard to alcohol use disorder (AUD) and alcoholic liver disease (ALD). To date, no studies have examined the brain-gut-microbiome (BGM) axis (which is the relationship between the gut, brain, and the bacteria within the gut) and sex-differences in AU...
What is the current status of trial NCT05007470?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2022-01-31. Estimated completion is 2025-09-01.
What conditions does trial NCT05007470 study?
This clinical trial studies the following conditions: Alcohol Use Disorder, Microbiome, Alcoholic Liver Disease.
What interventions are being tested in trial NCT05007470?
The interventions under investigation include: Placebo (OTHER), VSL #3 112.5 Capsule (DRUG).
Who is sponsoring clinical trial NCT05007470?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05007470 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder
RECRUITING · NA
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
RECRUITING · NA
-
AAT for Alcohol Use Disorder in Veterans
RECRUITING · NA
-
Testing a PTSD m-Health Intervention to Improve Alcohol Treatment Outcomes
RECRUITING · NA
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.